Navigation Links
Kent State Public Relations Students Host a Flash Mob to Launch National Donate Life Month
Date:4/2/2008

KENT, Ohio, April 2, 2008 /PRNewswire/ -- Kent State University public relations students organized a flash mob on the Kent campus today to spotlight the need for organ donors. April is National Donate Life Month.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080402/CLW132 )

A flash mob is defined as: "A large group of people who assemble suddenly in a public space, perform an unusual action for a brief period of time, then quickly disperse." The goal was to attract attention for the need for organ donations and to give Kent State students and others the opportunity to register.

Nationally 18 people will die each day waiting for an organ. In Ohio, 214 people died while waiting for an organ transplant in 2006.

The Kent State public relations students are participating in the Do It Now College Challenge, a statewide competition among 13 colleges and universities in Ohio sponsored by Donate Life Ohio. The goal of the campaign is to recruit 400,000 new organ donors in Ohio.

"Often, this is a subject that people don't want to think about it," says Julie McKinney, a junior public relations major and PRKent Do It Now team member. "Ultimately, organ donors save lives. We want to educate people about organ and tissue donation. And, hopefully, we can successfully encourage people to become donors."

Becoming a donor is simple. Ohio residents can sign-up while renewing their driver's license or visit the PRKent Do It Now team's Web site at http://www.doitnowohio.org/kent.

A single donor can save up to eight lives through organ donation and improve the lives of up to 50 people through tissue donation.

Kent State's campaign to increase organ donors was developed in the fall 2007 Public Relations Campaigns class and is being implemented by a team of Kent PR students throughout spri
'/>"/>

SOURCE Kent State University
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Report: Life And Death Differences in U.S. Child Well-Being Exist Between Top and Bottom States, Youths Up to Three Times More Likely to Die Before Adulthood in Some Parts of U.S.
2. State of Arizona to Use PocketCPR for Training Initiative on Hands-Only CPR
3. The Toy Industry Association Responds to Washington State Law Governing the Sale of Toys and the Governors Veto of Key Sections of the Bill
4. Front Line Caregivers from 16 States to Visit Capitol Hill to Urge State Congressional Delegation to Reject Medicare Cuts that Could Threaten Quality Care in Nations Nursing Homes
5. The United States Patent and Trademark Office Grants TransUnion Patent for Healthcare Financing Method
6. State of Cancer Care for Nations Poor and Minorities Is Focus of Conference in Washington
7. Statement in Response to SEIU United Healthcare Workers - Wests (UHW-W) Thursday Media Event
8. Radian Guaranty Inc. Eliminates Stated Income and Stated Asset Programs
9. CryoCor Reports Going Concern Statement and Receives Notification From Nasdaq Relating to Minimum Stockholders Equity
10. Mens Health Policy Center Hosts Petition to Protest Government Barrier to Prostate Cancer Medications
11. National, State Front Line Caregivers Warn About $64 Million Cut to Medicare Funding for Care of Michigan Seniors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...RANKLIN LAKES, N.J., Nov. 21 /PRNewswire-FirstCall...e for medical intervention in treating 88 percent ...percent of Americans treated for a chronic conditi... spending and 75 percent of all medical costs. A ...e years by Medco Health Solutions, Inc. (NYSE: M...
(Date:11/21/2008)...xperiments in mice find running increases producti... 21 (HealthDay News) -- In experiments in mice, ex...ction of brain stem cells usually seen with aging,...e restoration of the brain,s ability to stave off ...estore a neurochemical that is essential for the p...
(Date:11/21/2008)...EW YORK, Nov. 21 /PRNewswire/ -- For the second... years , McCann Healthcare Worldwide,s agency net...y network at the 22nd annual international RX Club...e agency offices won a total of 59 RX Club Awards ...e winning McCann Healthcare Worldwide agencies inc...
(Date:11/21/2008)...OSTON, Nov. 21 Innerscope Research...rm specializing in Emotional Response Measurement,...ves who will strengthen the,company,s research an...itiatives. , The three appointments, who de...Geoffrey Gill as Chief Financial Officer and Vice ...
Breaking Medicine News(10 mins):Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:Exercise Keeps the Brain Young 2Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 2Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 3Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 4Health News:Innerscope Research Strengthens Management Team With Three Executive Appointments 2
... a novel compound, CDDO-Im, shown to possess stron...imal models could soon revolutionize the treatment...n found to increase the intrinsic resistance to ca...g the function of enzymes that remove toxins from ...
...ier research institution has warned about the poss...ect to the genetic constitution of the much-dreade...hat this mutation could enable human-human bird fl...l affinity for human receptors. The company has a...
... is the world's most common liver infection. It sp...uals than the AIDS virus. It causes liver cirrhos...show that about two billion people (30 %) of the w...ected with the hepatitis B virus. Out of which 35...
...commended not to undergo frequent ultrasound scann...ove dangerous for the developing fetus, according ...Ultrasound images can show facial features, hair a...'s sex, reported health portal HealthCentral. Al...
Other Medicine News:Health News:New Compound Offers Hope In Liver Cancer Treatment 2Health News:Genetic Change In The H5N1 Virus Likely: Recombinomics Inc. 2
(Date:11/19/2008)...SAND OAKS, Calif., Nov. 19 /PRNewswire-FirstCall/ ...keda Oncology Company, a subsidiary of,Takeda Pha...ounced that,enrollment in the Phase 3 MONET1 tria...ith paclitaxel and carboplatin for the first-line ...(NSCLC) has been temporarily suspended,following ...
(Date:11/19/2008)...Jude scientists report basic findings on critical ...how to better treat an array of disorders , ,... -- Scientists at St. Jude Children,s Research Ho... one of the body,s enzyme workhorses called calpai...ers, calpains function in many cellular processes,...
(Date:11/19/2008)...RK, Del., Nov. 19 Isogen, a contra... sterile filling, today announced the first,phase...en was founded to,specifically address the proces...ated with the $2 billion highly-niched, low-volume...ing market segment. , Companies can invest ...
(Date:11/18/2008)...ON, November 19 NeuroDis...ervice provider and drug development Company,and...ex: 4565), a leading,international biopharmaceuti...s presenting further pivotal pre-clinical efficacy...g is a potential therapy for neuropathic pain and ...
Breaking Medicine Technology:Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3Isogen Launches Major New Facility to Address Global Biopharma Demand 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3Select Comfort Helps Families Sleep Better in Los Angeles 13410 1Select Comfort Helps Families Sleep Better in Los Angeles 13410 2Select Comfort Helps Families Sleep Better in Los Angeles 13410 3Cochlear implant recipients experience improvement in quality of life 13407 1A combination therapy of 3 vasodilators may treat portopulmonary hypertension 13404 1A combination therapy of 3 vasodilators may treat portopulmonary hypertension 13404 2Health Secretarys Statewide Tour to Discuss Health Insurance for All Pennsylvanians Makes Stop in Cambria County 13401 1Health Secretarys Statewide Tour to Discuss Health Insurance for All Pennsylvanians Makes Stop in Cambria County 13401 2
...NNA, Austria, June 11, 2007 /PRNewswire/ -- GlaxoS...nal, pivotal Phase III,study of its investigationa...A(R) (eltrombopag olamine). Data from this study,s... in a,statistically significant increase in platel...nts with chronic idiopathic,thrombocytopenic purpu...
...sults Presented at the 12th Congress of European H...ne 11, 2007 /PRNewswire-FirstCall/ --,Immunomedics...veloping monoclonal antibodies to treat cancer and... presented at the 12th Congress,of EHA in Vienna, ...h non-Hodgkin,s lymphoma (NHL) treated with a new,...
Other Medicine Technology:Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 2Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 3Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 4Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 5Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 6Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5
...e SR™ Hand Implant System utilizes the same ...cements. The SR™ Hand Implant System provid...stheses including minimal bone resection, surface ...us articular surfaces, retention and/or reposition...
For use in implant resection arthroplasty of the trapeziometacarpal joint in cases of rheumatoid, degenerative or post-traumatic arthritis.
The efficient choice for small joint replacement technology -- the Ascension Silicone MCP features a similar design to our PyroCarbon MCP and utilizes the same instrumentation for intra-operative fle
...e SR™ Hand Implant System utilizes the same ...cements. The SR™ Hand Implant System provid...stheses including minimal bone resection, surface ...us articular surfaces, retention and/or reposition...
Medicine Products: